Duchenne muscular dystrophy drug shows favourable PK profile
Satellos Bioscience has shared positive initial Phase I data for its small molecule drug candidate SAT-3247 at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, Texas.
SAT-3247 is designed to address progressive muscle loss in Duchenne muscular dystrophy (DMD) patients by aiming to restore regeneration in response to damage.
A Phase I trial with SAT-3247 is being conducted in healthy volunteers and adults with DMD (Phase Ia and Phase Ib, respectively).
In the Phase Ia, designed to assess the safety and tolerability of SAT-3247, 72 healthy volunteers were randomised across five single ascending dose (SAD) cohorts (including one food effect cohort) with single oral doses of up to 400mg, and four MAD cohorts with daily oral doses up to 240mg/day for seven days.
The data showed that SAT-3247 was safe and well tolerated across all healthy volunteer cohorts.
At predicted human efficacious dose levels, SAT-3247 did not display adverse clinical findings on any parameter measured, including clinical labs, vital signs, ECG, and physical exam. No moderate or greater drug-related adverse events were reported at any dose studied.
Phase 1a pharmokinetic (PK) data demonstrated consistency with results from the company’s preclinical studies.
These PK results confirm post-dose plasma concentrations of SAT-3247 are sustained at levels and time courses, which findings suggest are most likely to yield a therapeutic effect on muscle regeneration and strength.
“We are very pleased by these early clinical data reinforcing the translation of SAT-3247’s preclinical pharmacokinetic and safety profile,” said Frank Gleeson, Satellos Co-Founder and CEO. “We believe these clinical results support the potential for SAT-3247 to have a desirable therapeutic profile as a first-of-its-kind oral therapy for people living with DMD.”
Diana Spencer, Senior Digital Content Editor, DDW
